Building consensus on nomenclature and disease classification for ankylosing spondylitis: Results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 3, 2002, Pages

  Braun, J ^a,b   Sieper, J ^c  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Department of Gastroenterology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; ETHICS; GERMANY; HUMAN; INFLAMMATORY BOWEL DISEASE ASSOCIATED ARTHRITIS; LABORATORY DIAGNOSIS; MEDICAL SPECIALIST; NOMENCLATURE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RADIODIAGNOSIS; SCORING SYSTEM; SPONDYLOARTHROPATHY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0036893564     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.suppl_3.iii61     Document Type: Conference Paper

References (30)

1. Schumacher HR, Bardin T. The spondylarthropathies: Classification and diagnosis. Do we need new terminologies? Baillieres Clin Rheumatol 1998;12:551-65.
2. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
3. Arnett FC. Ankylosing spondylitis 1992: From Connor to transgenes. J lr Coll Physicians Surg 1993;22:207-11.
4. th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000;27:2185-92.
5. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
6. Benoist M. Historical perspective. Pierre Marie. Pioneer investigator in ankylosing spondylitis. Spine 1995;20:849-52.
7. Francois RJ, Eulderink F, Bywaters EG. Commented glossary for rheumatic spinal diseases, based on pathology. Ann Rheum Dis 1995;54:615-25.
8. Dougados M, Revel M, Khan MA. Spondylarthropathy treatment: Progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 1998;12:717-36.
9. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial. Lancet 2002;359:1187-93.
10. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
12. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: Is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999;38:878-82.
13. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
14. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig, J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
15. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 2000;59:428-33.
16. Breban MA, Vignon E, Claudepierre P, Saraux A, Wendling D, Lespessailles E, et al. Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of a 6 months follow-up open-label study [abstract]. Arthritis Rheum 2001;44(suppl):A222.
17. Francois RJ, Braun J, Khan MA. Entheses and enthesitis: A histopathologic review and relevance to spondyloarthritides. Curr Opin Rheumatol 2001;13:255-64.
18. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
19. Dougados M. Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 2001;68:557-63.
20. Schattenkirchner M. Indications and contraindications for systemic gold therapy. Wien Klin Wochenschr 1984(suppl);156:3-7.
21. Williamson L, Illingworth H, Smith D, Mowat A. Oral quinine in anklyosing spondylitis: A randomized placebo controlled double blind crossover trial. J Rheumatol 2000;27:2054-5.
22. Leirisalo-Repo M. Therapeutic aspects of spondyloarthropathies - A review. Scand J Rheumatol 1998;27:323-8.
23. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. Arthritis Rheum 1995;38:618-27.
24. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
25. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
26. Sieper J, Braun J. New treatment options in ankylosing spondylitis: A role for anti-TNF-alpha therapy. Ann Rheum Dis 2001;60(suppl III):iii58-61.
27. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
28. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-17.
29. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF alpha. Ann Rheum Dis 2001;60:750-5.
30. Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, et al. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: First clinical and laboratory experiences. Ann Rheum Dis 2000;59(suppl I):i85-9.